FERNANDO
LÓPEZ-RÍOS MORENO
Profesor asociado de Ciencias de la Salud
Manuel
Hidalgo Medina
Publicaciones en las que colabora con Manuel Hidalgo Medina (20)
2017
-
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
Oncotarget, Vol. 8, Núm. 21, pp. 35289-35300
-
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681
2016
-
Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 39, Núm. 3, pp. 236-242
2015
-
SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial
Clinical Cancer Research, Vol. 21, Núm. 21, pp. 4811-4818
2014
-
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 37, Núm. 2, pp. 117-121
-
Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
PLoS ONE, Vol. 9, Núm. 9
-
Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment
Clinical Cancer Research, Vol. 20, Núm. 9, pp. 2476-2484
-
Reply: Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
British Journal of Cancer
2013
-
Level of HER2 gene amplification predicts response and overall survival in her2-positive advanced gastric cancer treated with trastuzumab
Journal of Clinical Oncology, Vol. 31, Núm. 35, pp. 4445-4452
-
Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers
Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 503-508
-
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
British Journal of Cancer, Vol. 109, Núm. 4, pp. 926-933
-
The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre
Histopathology, Vol. 62, Núm. 4, pp. 609-616
2012
-
A comparison of EGFR mutation testing methods in lung carcinoma: Direct sequencing, real-time PCR and immunohistochemistry
PLoS ONE, Vol. 7, Núm. 8
-
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
Journal of Clinical Pathology, Vol. 65, Núm. 8, pp. 751-757
2011
2010
-
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model
Molecular Cancer Therapeutics, Vol. 9, Núm. 9, pp. 2582-2592
-
A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma
Journal of Molecular Diagnostics, Vol. 12, Núm. 3, pp. 292-299
2009
-
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
Molecular Cancer Therapeutics, Vol. 8, Núm. 2, pp. 310-314
-
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Molecular Cancer Therapeutics, Vol. 8, Núm. 6, pp. 1484-1493
2008
-
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Molecular Cancer Therapeutics, Vol. 7, Núm. 10, pp. 3275-3284